Dale Chappell

Dale Chappell, listed as senior executive, appears in our data through filings on Humanigen, Inc shares, published by SEC (Form 4). We count 91 filings; the first trade dates from 27 February 2018 and the latest from 18 October 2023.

In open-market terms, that means 13 purchases worth €7.3M on one side and 72 sales worth €57.7M on the other. Netting one side against the other leaves €50.4M of net selling. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. In 2023 alone, the filings show no purchases and 3 sales.

Half of the purchases are above €230k and half below. On 3 out of 13 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster.

The latest filing, published on 20 October 2023, reports an open-market sale of €792 in Humanigen, Inc. The most recent open-market purchase was published on 20 May 2022, 1,618 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.